Skip to main content

Table 3 Univariate and multivariate analyses of factors associated with overall survival

From: A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment

Variables Univariate Multivariate
HR 95%CI p value HR 95%CI p value
Lower Upper Lower Upper
ENZ vs ABI 1.280 0.873 1.884 0.205 1.105 0.810 1.507 0.529
Metastasis vs non-metastasis 1.200 0.835 1.719 0.328 1.412 1.011 1.970 0.043
Gleason score ≥ 8 vs Gleason score < 8 0.810 0.566 1.148 0.232 1.004 0.731 1.379 0.981
Age ≥ 75.6 (median) vs < 75.6 1.100 0.770 1.571 0.601 0.988 0.729 1.338 0.938
DOC treatment vs non-DOC treatment 2.070 1.410 3.045 < 0.001 2.160 1.571 2.970 < 0.001
NLR > 3.02 vs ≤3.02 2.070 1.094 2.300 0.015 2.115 1.540 2.906 < 0.001
ALP > 274 (median) vs ≤274 1.580 1.295 2.760 < 0.001 2.189 1.579 3.035 < 0.001
LDH > 220 (median) vs ≤220 1.790 1.234 2.597 0.002 2.284 1.647 3.168 < 0.001
  1. HR Hazard ratio, CI Confidential interval, ABI Abiraterone, ENZ Enzalutamide, DOC Docetaxel
  2. NLR Neutrophil to lymphocyte ratio, ALP Alkaline phosphatase, LDH Lactate dehydrogenas